Premium
5FU infusion with mitomycin‐C versus 5FU infusion with methyl‐CCNU in the treatment of advanced colon cancer. A southwest oncology group study
Author(s) -
Buroker Thomas,
Kim P. N.,
Groppe Carl,
McCracken Joseph,
O'Bryan Robert,
Panettiere Frank,
Coltman Charles,
Bottomley Richard,
Wilson Henry,
Bonnet John,
Thigpen Tate,
Vaitkevicius V. K.,
Hoogstraten Barth,
Heilbrun Lance
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co;2-s
Subject(s) - medicine , mitomycin c , bolus (digestion) , colorectal cancer , randomized controlled trial , oncology , cancer , chemotherapy , fluorouracil , surgery , urology
The Southwest Oncology Group (SWOG) in a randomized trial evaluated 5FU infusions in combination with either Mitomycin‐C or Methyl‐CCNU in patients with disseminated large bowel cancer. A response rate of 18% was noted on the 5FU‐Mitomycin limb as compared to 16% on the Methyl‐CCNU arm (p = .39). Median survival for all treated patients was 43 weeks on both arms. Myelosuppression was found to be more significant on the Mitomycin‐C arm. Regression analysis demonstrated that performance status, sex, and primary site were significant pretreatment characteristics for predicting survival. The response rates associated with this burdensome method of 5FU administration in combination with either Mitomycin‐C or Methyl‐CCNU appear to offer little advantage over bolus 5FU alone.